Santhera Pharmaceuticals Holding AG: Vamorolone NDA mid-cycle review meeting by FDA completed

Pratteln, Switzerland, and Rockville, MD, USA, April 25, 2023 - Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce the successful completion of the mid-cycle review meeting

Related Keywords

United States ,France ,Switzerland ,Pratteln ,Switzerland General ,United Kingdom ,Swiss ,America ,Eric Hoffman ,Eva Kalias ,Shabir Hasham ,Reveragen Biopharma ,European Medicines Agency ,Santhera Pharmaceuticals Holding ,Drug Administration ,Regulatory Agency ,National Institutes Of Health ,Us Department Of Defense ,Reveragen Biopharma Inc ,Duchenne Research Fund ,Head Investor Relations Communications ,Chiesi Group ,European Commission ,Santhera Pharmaceuticals ,Advisory Committee Meeting ,Muscular Dystrophy Association United States ,Foundation To Eradicate Duchenne ,Life Science Alliance ,Advisory Committee ,Chief Medical Officerof ,Orphan Drug ,Fast Track ,Rare Pediatric Disease ,Promising Innovative Medicine ,Proc Natl Acad Sci United States ,United Kingdom Medicines ,North America ,Parent Project Muscular Dystrophy ,Eradicate Duchenne ,Save Our Sons ,Action Duchenne ,Defeat Duchenne ,National Institutes ,Head Investor Relations ,Santhera ,Pharmaceuticals ,Molding ,Vamorolone ,Cycle ,Review ,Meeting ,Ompleted ,